GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: JNJ 2463 | JNJ-2463 | RYI-018 | RYI018
Compound class:
Antibody
Comment: Nimacimab (RYI-018; Skye Bioscience) is a humanized IgG4 anti-cannabinoid receptor 1 (CB1) monoclonal antibody. It acts to inhibit receptor function and is peripherally restricted.
Based on peptide sequence matches for antibody heavy and light chains between the INN record and patent US10308712B2, nimacimab appears to be clone PIC4-H2-IgG4 therein [2]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 11023 | nimacimab |
| Synonyms |
| JNJ 2463 | JNJ-2463 | RYI-018 | RYI018 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 922 |
| Other databases | |
| Search PubMed clinical trials | nimacimab |
| Search PubMed titles | nimacimab |
| Search PubMed titles/abstracts | nimacimab |
